Spark Therapeutics

This weekend's Barron's takes a look at what the latest monster media deal will mean for the industry. Other featured articles offer the best and worst income picks for the coming year and a regional airline that is ready to take off. A gene therapy-focused biotech and real estate...

One of the biggest biotech conferences of the year is around the corner. The 59th annual meeting of the American Society of Hematology, or ASH, is Dec. 9-12 in Atlanta. It's likely to serve as a make-or-break catalyst for many companies researching blood-related diseases and disorders. About 3,...

This weekend's Barron's cover story three stock picks on the forefront of gene therapy. Other featured articles discuss a theme-park operator may have peaked and a database giant that has been slow to build a cloud business. Artificial intelligence plays and consumer discretionary stocks are also...

Shares of Spark Therapeutics Inc (NASDAQ: ONCE) opened higher by more than 40 percent on Monday. Spark's product candidate, SPK-RPE65, targets a group of rare blinding conditions known as inherited retinal dystrophies. Spark announced on Monday its SPK-RPE65 met the goals of a late-stage study....

Shake Shack (NYSE: SHAK) will be this week’s highlight IPO if its 5 million-share offering raises the expected $92 million in proceeds. With a price between $14 and $16, the company will be valued at nearly $570 million. Shake Shack describes itself as “a modern day '...